U.S. Markets closed
  • S&P 500

    4,241.84
    -4.60 (-0.11%)
     
  • Dow 30

    33,874.24
    -71.34 (-0.21%)
     
  • Nasdaq

    14,271.73
    +18.46 (+0.13%)
     
  • Russell 2000

    2,303.47
    +7.52 (+0.33%)
     
  • Crude Oil

    73.28
    +0.20 (+0.27%)
     
  • Gold

    1,778.70
    -4.70 (-0.26%)
     
  • Silver

    25.93
    -0.18 (-0.67%)
     
  • EUR/USD

    1.1936
    -0.0007 (-0.0597%)
     
  • 10-Yr Bond

    1.4870
    +0.0150 (+1.02%)
     
  • Vix

    16.32
    -0.34 (-2.04%)
     
  • GBP/USD

    1.3968
    +0.0021 (+0.1481%)
     
  • USD/JPY

    110.9530
    +0.3180 (+0.2874%)
     
  • BTC-USD

    33,334.18
    +771.12 (+2.37%)
     
  • CMC Crypto 200

    800.68
    -9.51 (-1.17%)
     
  • FTSE 100

    7,074.06
    -15.95 (-0.22%)
     
  • Nikkei 225

    28,874.89
    -9.24 (-0.03%)
     

Pfizer puts off investor day, reports two late-stage study results in advance

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
·1 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

March 18 (Reuters) - Pfizer Inc on Wednesday reported results from two late-stage studies ahead of schedule as it put off its March 31 investor day amid the coronavirus outbreak.

The drugmaker said its experimental treatment, abrocitinib, was effective in treating atopic dermatitis in combination with topical therapies in a late-stage study.

In addition, it also reported positive top-line results from another late-stage study testing its pneumococcal conjugate vaccine candidate in adults 18 years of age or older not previously vaccinated against pneumococcal disease, a type of bacterial infection.

(Reporting by Manojna Maddipatla in Bengaluru; Editing by Arun Koyyur)